Not available
Quote | Zai Lab Limited (NASDAQ:ZLAB)
Last: | $20.81 |
---|---|
Change Percent: | 7.27% |
Open: | $19.93 |
Close: | $19.40 |
High: | $21.07 |
Low: | $19.93 |
Volume: | 512,795 |
Last Trade Date Time: | 05/20/2024 03:00:00 am |
News | Zai Lab Limited (NASDAQ:ZLAB)
2024-05-20 01:30:00 ET Summary Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments. Zai Lab reported China’s NMPA approved Augtyro ...
Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on comprehensive clinical data demonstrating robust activity of SUL-DUR against carbapenem-resi...
Message Board Posts | Zai Lab Limited (NASDAQ:ZLAB)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Zai Lab Limited Company Name:
ZLAB Stock Symbol:
NASDAQ Market:
Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on comprehensive clinical data demonstrating robust activity of SUL-DUR against carbapenem-resi...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in May and June 2024: J.P. Morgan 20th Annual Global China Summit Panel Discussion: Thursday, May 23, 2024, 10:00...
sBLA submission based on positive results from the ADHERE trial, the first positive global neonatal FC receptor (FcRn) pivotal study for CIDP There are currently no approved therapies available in China for this serious autoimmune disease Milestone underscores Zai Lab’s ope...